



Shortly thereafter, the State of Georgia filed the instant Motion to Remand [Doc. 13] for lack of subject matter jurisdiction. For the reasons that follow, the State of Georgia's motion [Doc. 13] is **GRANTED**.

## **I. FACTUAL AND PROCEDURAL BACKGROUND**

### The Regenerative Medicine Industry:

This action arises against the backdrop of the regenerative medicine industry. Generally speaking, regenerative medicine involves replacing, engineering, or regenerating human cells, tissues, or organs to establish, restore or enhance normal cell function. (Complaint, Doc. 1-2 ¶ 9.) This can be accomplished with cell therapies, therapeutic tissue-engineering products, human cell and tissue products, and certain combination products involving cells and devices. (*Id.*) Regenerative medical products and procedures are regulated by the U.S. Food and Drug Administration ("FDA") under the 1938 Food, Drug and Cosmetic Act ("FDCA") and the Public Health Service Act ("PHSA"). (*Id.* ¶ 10.) At present, the FDA has approved the use of stem cell products only for certain types of stem cells, "blood-forming" stem cells, and for specific disorders, such as ones that affect the production of blood. (*Id.*) Non-approved stem cell products are "investigational" products that are currently involved in FDA review processes which includes investigations into the product's effectiveness and safety, such as through clinical trials. (*Id.* ¶ 11.)

Over the last few years, the FDA, its Commissioner, its Director of the Center for Biologics Evaluation and Research, and industry physicians, scientists, and

regulatory experts have warned about unproven and unapproved regenerative medicine products — including stem cell, exosome, or other similar products — that are “uncontrolled experimental procedures” that cost patients both financially and physically. (*Id.* ¶¶ 11-13.) The FDA has issued “consumer alerts” concerning certain stem cell products, including ones derived from human umbilical cord blood, Wharton’s Jelly, or amniotic fluid, notifying consumers that none of these products have been approved to treat any orthopedic condition, neurological disorder, or cardiovascular or pulmonary disease. (*Id.* ¶ 12.) These authorities have also condemned the practice of advertising and offering of unproven stem cell products, stating that the “aggressive marketing approach” by certain companies, which claim that their particular stem cell products are safe and effective, is not supported by the existing scientific literature. (*Id.* ¶ 13.) Similarly, the Federal Trade Commission has warned that marketers should not create confusion by playing “fast and loose” with the facts, as the phrase “stem cell treatment” covers a broad range of therapies, from promising research to fraud. (*Id.* ¶ 14.)

Elite’s Business:

During the relevant time period, Defendant Elite operated a medical practice that advertised and offered regenerative medicine products to Georgia consumers to treat, cure, and mitigate various diseases and health conditions. (*Id.* ¶ 4.)



(*Id.* ¶ 34.) Defendant Paulk owned and managed the day-to-day operations of Elite, had the sole authority to approve all marketing content relating to the regenerative medicine products offered by Elite, and regularly communicated with the company that disseminated marketing content on behalf of Elite. (*Id.* ¶ 5.)

The regenerative medicine products Elite advertised and offered were not ones it manufactured or produced; rather, Elite purchase these products from third-party manufactures. (*Id.* ¶ 17.) These third-party products were processed or derived from placental tissue and Wharton's jelly of the umbilical cord. (*Id.* ¶¶ 18-21.) The manufactures have identified these products as human cellular and tissue products ("HCT/P") that are regulated by the FDA. (*Id.* ¶ 23.) None of the products offered by Defendants have been approved by the FDA. (*Id.* ¶ 27.)

According to the Complaint, Defendants made false and misleading representations regarding their products' safety and effectiveness on their website, in video-taped "testimonials," in newspapers, on social media, in brochures, by email, and at seminars. (*Id.* ¶¶ 34,40,41,45,50.) For example, as alleged,

Defendants represented, expressly or by implication, that their products were safe and effective by citing to studies and reports for *other, different* stem cell therapies and products. (*Id.* ¶ 30.) These other stem cell products are derived from different sources (such as bone marrow), do not contain the same ingredients, and are not processed or manufactured using the same processes. (*Id.* ¶ 32.)

In addition, the State alleges that Elite made a series of other misrepresentations in promoting its products. The Complaint alleges that Elite advertised as having a staff of medical doctors involved in providing the regenerative therapies — for example, posting a video with a paid actor purporting to be a medical doctor — when in reality Elite only employed medical doctors as independent contractors for the limited purpose of administering injections to consumers. (*Id.* ¶¶ 37-38.) Seminars were conducted by chiropractors wearing white lab coats who introduced themselves as “doctor.” (*Id.* ¶ 49.) Defendants also allegedly sent out emails to consumers with success stories from professional athletes to substantiate their products; however, the stem cell therapies/ products used by the athletes were different than the ones provided by Elite. (*Id.* ¶ 46.) As another example cited in the Complaint, Defendants’ seminar materials included PowerPoint presentations, indicating that Human Cellular Tissue is not regulated by the FDA, as shown below. (*Id.* ¶ 51.)

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.